Galimedix Therapeutics

Galimedix Therapeutics, Inc., headquartered in the United States, is a Phase 2 clinical-stage pharmaceutical and ophthalmology company developing transformative treatments based on a novel mechanism of action targeting the common cause of several neurodegenerative diseases: toxic oligomers of β-amyloid (Aβ). The initial focus is on our Phase 2 eye drop treatment for two leading causes of blindness: dry age-related macular degeneration (dry AMD) of the retina and glaucoma, with Alzheimer’s disease treatment underway. For the long-term treatment required for glaucoma and dry AMD, eye drop administration is more convenient and may offer significant safety and convenience/tolerability advantages over commonly used direct ocular injections.